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associated with introduction and subsequent discontinuation of tamsulosin in patients naïve to this drug with the aid of an anterior
OCT system.
Methods: The study was carried out on 7 patients (14 eyes) naïve to tamsulosin and with benign prostatic hypertrophy (BHP). Mea-
surements taken by Vistante OCT were done pre- and post-dilation of the following: pupil size, iris dilator muscle region (DMR)
thickness, sphincter muscle region (SMR) thickness, and anterior chamber depth. These measurement were taken at Day 0 (tam-
sulosin naive), Day 30 (after one month of tamsulosin, the treatment period) and day 60 (after one month of no tamsulosin, the
discontinuation period).
Results: Post-dilation pupil diameter significantly increased during the discontinuation period (P = 0.047). Iris DMR thickness mea-
surements post-dilation significantly decreased during treatment (P = 0.00044), discontinuation (0.00011), and combined periods
(P = 0.000050). Anterior chamber depth measurements in post-dilation were significantly decreased during treatment
(P = 0.0016), discontinuation (P = 0.017), and combined periods (P = 0.00022).
Conclusion: Tamsulosin discontinuation effectively increases dilated pupil size, a measure that has been inversely linked to IFIS
incidence pre-operatively. Decreased DMR thickness in this short term likely illustrates changes aside from atrophy, such as vas-
cular changes. Decreased anterior chamber depths suggest aqueous humor production is decreased as well.
Keywords: Intraoperative floppy iris syndrome, Cataract surgery, Optical coherence tomography, Flomax, Tamsulosin, Benign
prostatic hypertrophy
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University.
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Benign prostatic hyperplasia (BPH) is a common condition
affecting 2.7% of men aged 45–49 years and as high as 24%
for men over 80 years old.1 Pharmacological treatment of
BPH involves the use of a1A-adrenoreceptor antagonists,such as tamsulosin. This drug is now known to many ophthal-
mologists through its association with iris changes that com-
plicate cataract surgery.2 These changes have been coined as
intraoperative floppy iris syndrome (IFIS) by Chang and
Campbell.3e:
al.com
ia. Fax:
tawa.ca
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pupil diameter is associated with increased risk of IFIS.4
Chang hypothesized that this was caused by a blockage of
a1A adrenoreceptors (a1A-AR) in the iris dilator muscle. Tam-
sulosin users have been observed to have decreased dilated
pupil diameters compared to control groups.5,6 Pupil diame-
ter decreases have also been observed with tamsulosin intro-
duced to tamsulosin-naïve patients.7
In addition to pupil diameter changes, it is hypothesized
that a1A-adrenoreceptor antagonists lead to loss of iris dilator
muscle tone and disuse atrophy due to chronic blockage of
the a1A receptor on the muscle.
3,8 This could explain both
the flaccid characteristic of the tissue as found during catar-
act surgery and the occurrence of IFIS despite discontinued
usage before surgery.9 In support of atrophy, it has been
found by optic coherence tomography, tamsulosin users have
decreased iris thicknesses in the dilator muscle region.6
The aim of this study was to quantify changes and
reversibility in pupil dilation and iris dilator muscle region
thickness associated with an introduction and subsequent dis-
continuation of tamsulosin in patients naïve to this drug with
the aid of an anterior OCT system. A small cohort of patients
on tamsulosin was followed longitudinally to see whether any
changes that may occur are reversible. To date, no other
study has examined the anterior chamber morphology of tam-
sulosin naïve patients with a discontinuation period.Patients and methods
Patients were recruited from the Urology Clinic and tested
at the Eye Clinic in Toronto Western Hospital. Testing
included 7 patients and 14 eyes, all of men in age range of
60–80 years old. There is no significant post void residual or
urinary retention in any of the selected patients. All patients
received an explanation of the risks involved and provided
informed consent. The inclusion criteria included any diagno-
sis of BPH, if Tamsulosin deemed clinically necessary and no
previous exposure to a1-adrenoreceptor antagonist. Exclu-
sion criteria were eye drop usage besides artificial tears (i.e.
mydriatics or a1-AR agonist), previous angle closure glau-
coma, Pseudoexfoliation syndrome, previous ocular surgery
(i.e. laser iridoplasty, cataract surgery), Horner’s syndrome,
ocular trauma and uveitis.
The study was carried out on 7 patients (14 eyes) with BPH
and naïve to tamsulosin usage. One patient was diabetic.
Anterior chamber OCT images of participants’ eyes wereFigure 1. An example of anterior chamber imaging by Carl Zeiss Medit
measurement. This imaging allows accurate measurement of pupil size, iris d
thickness, and anterior chamber depth (ASD).taken at 3 different points in time over a 2 month duration,
prior to tamsulosin, at the end of 30 day tamsulosin course,
and another 30 days after completion of therapy. Measure-
ments were made by OCT Visante software (Carl Zeiss Co.)
at each of the three points in time, before and after dilation
of each eye with Diophenyl-T eyedrops (Phenylephrine
Hydrochloride 5%; Tropicamide 0.8%).
Measurements of interest were as follows: pupil size, iris
dilator muscle region (DMR) thickness, iris sphincter muscle
region (SMR) thickness, and anterior chamber depth. These
were measured from the OCT images through use of the
anterior chamber OCT (Fig. 1).
All tests were performed in the same clinic with the same
instruments during the course of the study. Patients were
examined and evaluated for a complete eye history before
starting the study including in clinic pretest slit lamp biomi-
croscopy examination for the evaluation of anterior chamber,
pupils, diameter, and refractivity. Additionally, OCT imaging
measurements of pupil size measured between papillary mar-
gins, iris dilator muscle region (DMR) measured halfway
between the scleral spur and pupil margin and iris sphincter
muscle region (SMR) measured within anterior 0.75 mm from
pupil margin at the thickest and thinnest aspects were
recorded. The anterior chamber depth (ASD) measured from
the anterior border of lens to the posterior border of cornea
was also recorded. None of the patients experienced any uri-
nary symptoms or complications. There were no patients lost
to follow-up during the study.
Statistical analysis
Measurements for each eye at the start and end of the
treatment, discontinuation, or combined period were ana-
lyzed using SPSS version 20.0 (IBM Inc., Chicago, Illinois,
USA). Shapiro-Wilk test was used to test for normality and
the data were not normally distributed; hence, Friedman test
was used to compare the paired data. Each eye was treated
as an independent sample. The null hypothesis was set as no
difference between the start and end of a period for all mea-
sures of pupil diameter, iris thicknesses, and anterior cham-
ber depth. Significance was considered as P < 0.05.Results
The post-dilation pupil diameter was found to be
significantly increased during the discontinuation periodec’s VisanteTM OCT system demonstrating standardized positions of
ilator muscle region (DMR) thickness, iris sphincter muscle region (SMR)
Table 1. Pupil sizes expressed as mean ± standard deviation in mm.
Stage of tamsulosin usage Treatment period (Day–30) Discontinuation period
(Day–60)
Combined period (Day–60)
Day 0 (before
tamsulosin exposure)
Day 30 (after 1
month of exposure)
Day 60 (after 1 month of
discontinuation)
Difference between
start and end
P-
value
Difference between
start and end
P-
value
Difference between
start and end
P-
value
Pupil diameter change with
dilation
2.80 ± 0.70 2.81 ± 0.79 3.12 ± 0.62 0.02 ± 0.80 0.92 0.31 ± 0.87 0.24 0.32 ± 0.73 0.17
Pre-dilation pupil diameter 3.21 ± 0.64 2.96 ± 0.56 2.98 ± 0.46 0.25 ± 0.46 0.064 0.02 ± 0.56 0.92 0.23 ± 0.49 0.12
Post-dilation pupil diameter 5.93 ± 0.56 5.75 ± 0.81 6.07 ± 0.63 0.18 ± 0.59 0.33 0.32 ± 0.49 0.047 0.14 ± 0.39 0.26
Table 2. Dilator muscle region thicknesses expressed as mean ± standard deviation in mm.
Stage of tamsulosin usage Treatment period (Day 0–30) Discontinuation period (Day
30–60)
Combined period (Day 0–60)
Day 0 (before
tamsulosin
exposure)
Day 30 (after 1
month of
exposure)
Day 60 (after 1 month
of discontinuation)
Difference
between start and
end
P-value Difference
between start and
end
P-value Difference
between start and
end
P-value
DMR pre-dilation thickness 0.51 ± 0.053 0.48 ± 0.043 0.46 ± 0.041 0.030 ± 0.023 0.00032 0.019 ± 0.018 0.0015 0.049 ± 0.031 0.000051
DMR post-dilation thickness 0.63 ± 0.054 0.59 ± 0.061 0.57 ± 0.057 0.041 ± 0.032 0.00044 0.013 ± 0.0090 0.00011 0.054 ± 0.034 0.000050
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Table 4. Thickest and thinnest sphincter muscle region thicknesses expressed as mean ± standard deviation in mm.
Stage of tamsulosin usage Treatment period (Day 0–30) Discontinuation period (Day
30–60)
Combined period (Day 0–60)
Day 0 (before
tamsulosin exposure)
Day 30 (after 1 month
of exposure)
Day 60 (after 1 month of
discontinuation)
Difference Between
Start and End
P-
value
Difference between
start and end
P-
value
Difference between
start and end
P-
value
Thickest pre-
dilation SMR
0.56 ± 0.10 0.56 ± 0.076 0.56 ± 0.077 0.0036 ± 0.040 0.71 0.00071 ± 0.0027 0.32 0.0029 ± 0.040 0.80
Thickest post-
dilation SMR
0.58 ± 0.064 0.58 ± 0.068 0.58 ± 0.063 0.0025 ± 0.011 0.44 0.0017 ± 0.0083 0.48 0.0042 ± 0.012 0.21
Thinnest pre-
dilation SMR
0.31 ± 0.029 0.31 ± 0.022 0.31 ± 0.023 0.00071 ± 0.011 0.83 0.00071 ± 0.0062 0.71 0.0 ± 0.013 0.998
Thinnest post-
dilation SMR
0.31 ± 0.026 0.30 ± 0.024 0.31 ± 0.022 0.0058 ± 0.0090 0.047 0.0042 ± 0.0090 0.13 0.0017 ± 0.0072 0.43
Table 3. Ratio value between dilator muscle region and sphincter muscle region expressed as mean ± standard deviation.
Stage of tamsulosin usage Treatment period (Day 0–30) Discontinuation period (Day
30–60)
Combined period (Day 0–60)
Day 0 (before
tamsulosin
exposure)
Day 30 (after 1
month of exposure)
Day 60 (after 1 month
of discontinuation)
Difference
between start and
end
P-
value
Difference
between start and
end
P-
value
Difference
between start and
end
P-value
Pre-dilation DMR/SMR ratio 0.92 ± 0.18 0.88 ± 0.15 0.85 ± 0.13 0.047 ± 0.049 0.0028 0.029 ± 0.044 0.024 0.076 ± 0.066 0.00080
Post-dilation DMR/SMR ratio 1.1 ± 0.14 1.0 ± 0.13 1.0 ± 0.11 0.076 ± 0.066 0.0020 0.023 ± 0.022 0.0042 0.099 ± 0.073 0.00061
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154 A. Al-Kharashi et al.(+0.32 ± 0.49 mm, P = 0.047). Other changes were not statis-
tically significant. See Table 1 for the pupil diameter findings.
Iris DMR thicknesses at pre-dilation and post-dilation were
significantly decreased during treatment, discontinuation,
and combined periods. Changes in pre-dilation measure-
ments during these periods, respectively, were 0.030 ±
0.023 mm (P = 0.00032), 0.019 ± 0.018 mm, P = 0.0015
and 0.049 ± 0.031 mm, P = 0.000044. Changes for post-
dilation measurements during these periods, respectively,
were 0.041 ± 0.032 mm (P = 0.00044), 0.013 ±
0.0090 mm (P = 0.00011), and 0.054 ± 0.034 mm
(P = 0.000050). See Table 2 for iris dilator muscle region
thickness findings.
DMR/SMR ratios at pre-dilation and post-dilation were
significantly decreased during treatment, discontinuation,
and combined periods. Changes in pre-dilation measure-
ments during these periods, respectively, were
0.047 ± 0.049 (P = 0.0028), 0.029 ± 0.044 (P = 0.024) and
0.076 ± 0.066 (P = 0.00080). Changes in post-dilation mea-
surements during these periods, respectively, were
0.076 ± 0.066 (P = 0.0020), 0.023 ± 0.022 (P = 0.00042),
and 0.099 ± 0.073 (P = 0.000061). See Table 3 for ratios
of DMR to SMR for each eye.
There was no significant change in either thickest or thin-
nest SMR measurement at pre- or post-dilation during any
period of the study. See Table 4 for SMR thickness values.
Post-dilation anterior chamber depth measurements were
significantly decreased during treatment, discontinuation,
and combined periods. Changes in post-dilation measure-
ments during these periods, respectively, were
0.023 ± 0.019 (P = 0.0017), 0.026 ± 0.033 (P = 0.016),
and 0.049 ± 0.032 (P = 0.00022). See Table 5 for anterior
chamber depth values.Ta
b
le
5
.
A
nt
er
io
r
ch
am
b
er
d
ep
th
ex
p
re
ss
ed
as
m
ea
n
±
st
an
d
ar
d
d
ev
ia
ti
o
n
in
m
m
.
St
ag
e
o
f
ta
m
su
lo
si
n
us
ag
e
D
ay
0
(b
ef
o
re
ta
m
su
lo
si
n
ex
p
o
su
re
)
D
ay
30
(a
ft
er
1
m
o
nt
h
o
f
ex
p
o
su
re
)
D
ay
60
(a
ft
er
1
m
o
n
d
is
co
nt
in
ua
ti
o
n)
P
re
-d
ila
ti
o
n
A
C
D
2.
67
±
0.
40
2.
66
±
0.
39
2.
66
±
0.
39
P
o
st
-d
ila
ti
o
n
A
C
D
2.
78
±
0.
38
2.
76
±
0.
37
2.
73
±
0.
39Discussion
The post-dilation pupil diameter was found to increase
during the discontinuation period. This may be due to a
decreased concentration of tamsulosin, which has a half-life
of 14 h and is a competitive antagonist.10 In a study by Parssi-
nen, tamsulosin concentrations in aqueous humor were
below quantification in one patient after a 21 day pause of
therapy.11 Our findings suggest that pupil size changes sec-
ondary to tamsulosin may be reversible in the short-term.
A second contributing factor toward greater pupil diame-
ter is upregulation of adrenergic receptors in response to
drug exposure. This idea was proposed in a study with rats
exposed to 1 month of tamsulosin treatment followed by
1 month of washout.12 It theoretized the maintenance of
upregulated a1a-AR washout in order to explain dilated pupil
diameters of rats that were, albeit statistically insignificant,
larger at washout than baseline when dilated with an alpha
agonist but not with another mydriatic agent. The results in
our study are similar. In an analysis by Panagis, an eye of sig-
nificantly longer exposure did not show upregulation on
immunoreactive histopathologic analysis.13
Clinically, the possibility of reversibility of dilated pupil
diameter with discontinuation of tamsulosin is important.
Decreased diameters have been shown to have both an
increase in severity and frequency of IFIS.4,14
We found that DMR thickness decreased during treat-
ment and, surprisingly, also during discontinuation of the
Anterior segment OCT changes associated with tamsulosin 155treatment. Decreased thickness during discontinuation per-
iod may be explained by the effect of the residual levels of
the drug. Similar to this study, Prata found decreased DMR
and DMR/SMR ratio values on OCT imaging of eyes exposed
to tamsulosin for an average 28.2 months.6 Iris dilator muscle
atrophy is also a plausible explanation to account for some of
the thickness decreases in the Prata study.
Histologically, the muscular layer is a small portion of the
iris thickness and its atrophy could not solely account for
decreased thickness in this study. Nonetheless, atrophy
within iris dilator muscle has been found in eyes exposed to
longer durations of tamsulosin.8 There are likely to be other
components of the iris, such as the vasculature, which may
account for the iris thickness changes in this study. Much of
the iris structure is vascularized stroma composed of arteri-
oles that do not bifurcate or anastamose.15 Immunohisto-
chemical analysis by Panagis showed markedly decreased
a1a-AR immunoreactivity of the arteriolar lumen of IFIS iris tis-
sue compared to non-IFIS tissue.13 In contradiction to this, a
study of rat iris arterioles showed a pharmacological
response of these blood vessels consistent with the activation
of a1b-AR, but not a1a-AR.
16 However, this may be accounted
for by difference between species. Vasculature changes may
be dynamic as opposed to morphological as Panagis did not
show iris morphological changes in IFIS eyes compared to
control. A similar observation was found in a cadaveric study
by Santaella that found no significant difference in iris
stroma.8
Despite lack of documented effect of an a1a-AR on iris
arteriolar structure or function, Panagis proposed that iris
vasculature provides the structural support for the iris and
has the ability to coil and uncoil to allow for iris dilation.13
The loss of this arteriole coiling ability would decrease iris
dilation.13 This would be consistent with our findings if this
proposed coiling is structurally thinner. Vasoconstriction is
also a possible explanation for iris thickness changes but
a1-AR antagonism by prazosin has been observed to block
vasoconstriction in rat iris arterioles.16 The effect of a selec-
tive a1A-AR antagonist such as tamsulosin on vascular func-
tion is not known. Furthermore, vascular dysfunction may
also lead to iris dilator muscle atrophy due to a deterioration
of arteriolar nutritive functions.
The findings of decreased anterior chamber depth by OCT
were found only in dilated pupils. This may occur as a result
of decreased aqueous humor. Alpha-1 ARs play a role in
aqueous humor dynamics. Specific agonists for a1-ARs
increase intraocular pressure while specific antagonists
decrease intraocular pressure.17 A study by Zhan found that
bunazosin (an a1-AR antagonist) treatment significantly
decreased intraocular pressure with increased uveoscleral
outflow in rabbits.18 A study by Krupin found prazosin (an
a1-AR antagonist) decreased aqueous humor production
but did not change outflow.19 In another study of prazosin,
Chiou observed 55% reduction in aqueous humor production
and 25% reduction in aqueous humor outflow during a 3 h
period in the cat eye model.20 It would thus be expected that
another a1-AR antagonist such as tamsulosin would also
decrease aqueous humor volumes. A study by Suzuki found
that the mRNA levels of different a1-AR subtypes in the ciliary
body were 99.2% comprised of the a1-AR subtypes.
17 The
selectivity of tamsulosin for the a1A-AR subtype and its mRNA
predominance in the ciliary body provides a physiologicalpathway for decreased aqueous humor as made evident in
our study by decreased anterior chamber depth.10 Our study
suggests that tamsulosin affects aqueous humor production
and may provide benefit to glaucoma therapy. Tamsulosin’s
effect on glaucoma has not been studied to our knowledge
and provides an avenue for further research into its effects
on anterior chamber depth, aqueous humor production and
outflow, and intraocular pressure.
In conclusion, the findings of this study suggest pupil
diameter changes are reversible and suggest possible
reversibility of IFIS as well for short-term users. It demon-
strates iris thickness effects but not the significance of this
in relation to IFIS incidence remains to be determined. Our
study demonstrates novel findings of an effect of tamsulosin
on anterior chamber depth. This is likely through aqueous
humor changes and is of relevance to glaucoma treatment.
The findings of this study are limited by the small cohort size
as well as a lack of placebo group to compare findings. Fur-
thermore, the treatment period is short and conclusions can-
not be extrapolated to long-term usage. Although the
discontinuation follow-up period was thirty days, findings
such as decreased DMR may normalize given longer follow-
up. Directions for future research include anterior chamber
depth, aqueous humor and intraocular pressure changes with
tamsulosin in the context of glaucoma treatment effects. Fur-
thermore, it remains to be determined whether or not dis-
continuing tamsulosin in short-term users has an effect on
IFIS incidence and severity.Conflict of interest
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